Bright Minds Biosciences files amended Form 6-K

Bright Minds Biosciences Inc. filed an amended Form 6-K to update a prior submission for November 2025.

Accepted by SEC EDGAR 11/17/2025 - 03:58 PM EST

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K/A

Rhea-AI Filing Summary

Bright Minds Biosciences Inc. filed an amended Form 6-K to update a prior submission for November 2025. The amendment mainly clarifies that Exhibit 99.1, a news release dated November 6, 2025, is incorporated by reference into two existing Form F-3 shelf registration statements.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Bright Minds Biosciences (DRUG) report in this Form 6-K/A?

Bright Minds Biosciences files an amended Form 6-K to update a prior November 2025 report. It focuses on how a November 6, 2025 news release is incorporated into existing Form F-3 registration statements.

What is Exhibit 99.1 in Bright Minds Biosciences’ Form 6-K/A?

Exhibit 99.1 is a news release dated November 6, 2025. The amendment specifies that this news release is formally incorporated by reference into two Form F-3 registration statements for Bright Minds Biosciences.

Which registration statements does Bright Minds Biosciences (DRUG) reference?

The company incorporates Exhibit 99.1 into two Form F-3 registration statements. One was originally filed on February 5, 2025, and the other was originally filed on August 25, 2025.

Why did Bright Minds Biosciences file this Form 6-K/A amendment?

The amendment documents that the November 6, 2025 news release is incorporated by reference into specific Form F-3 registration statements. It is an administrative update rather than a detailed financial or operational disclosure.

Does this Bright Minds Biosciences Form 6-K/A include financial results?

The amendment does not present financial tables or earnings data. It focuses on legal and disclosure mechanics, specifying how a November 6, 2025 news release ties into existing Form F-3 registration statements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K/A

Amendment No. 1

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File No. 001-40997

BRIGHT MINDS BIOSCIENCES INC.
(Translation of registrant's name into English)

19 Vestry Street,
New York, NY 10013
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F [ X ] Form 40-F [ ]

INCORPORATION BY REFERENCE

Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K is incorporated by reference into our (a) registration statement on Form F-3 (File No. 333-284694), originally filed on February 5, 2025, and the prospectus thereto filed on February 14, 2025, and (b) registration statement on Form F-3 (File No. 333-289851), originally filed on August 25, 2025.

SUBMITTED HEREWITH

Exhibits
99.1	News Release dated November 6, 2025

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BRIGHT MINDS BIOSCIENCES INC.

/s/ Ryan Cheung

_________________________
Ryan Cheung
Chief Financial Officer

Date: November 17, 2025

Source: View Original Filing on SEC EDGAR